• Mashup Score: 5
    The Texas Heart Institute Cardiovascular Disease Fellowship Class of 2026 - 10 month(s) ago

    Over the past six decades, The Texas Heart Institute’s cardiology fellowship program at Baylor St. Luke’s Medical Center has been one of the most prestigious training grounds in the country, and today we proudly welcome six exceptional young physicians. Please join the Cardiovascular Disease Fellowship Program in welcoming the new cohort of first-year fellows.

    Source: The Texas Heart Institute
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      Please join us in welcoming the new cohort of six first-year fellows to the Cardiovascular Disease Fellowship Program! @ConchaDaniella, Feng Gao, @BGudenkaufMD, Colin Hinkamp, @niru_krish & Matthew Nardi #THIFellowship https://t.co/E2ggVeXHPZ https://t.co/KoAX5bGWma

  • Mashup Score: 0
    The Role of Transcatheter Aortic Valve Implantation in Patients With Bicuspid Valves in 2023 - 10 month(s) ago

    Bicuspid aortic valve (BAV) is the most common congenital heart defect, occurring in 1% to 2% of the general population.1 Compared with individuals having normal tricuspid aortic valves, those with BAVs are more likely to develop calcification on valve leaflets and raphe and dilation of the ascending aorta (aortopathy)—and at a much earlier age. For highly select patients with severe BAV…

    Source: Allen Press
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      The role of transcatheter aortic valve implantation in patients with bicuspid valves in 2023 | #THIPubs #DrZKrajcer @MiladElHajjMD #THIFellowship | @Texas_Heart #THIJournal https://t.co/rDlXKTTVtZ

  • Mashup Score: 2
    Heart Failure Drug Therapy: New Treatments, New Guidelines - 1 year(s) ago

    In recent years, several new medications have proven useful in reducing heart failure–related morbidity and mortality. The result is a broader therapeutic armamentarium to treat both heart failure with reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] <40%) and heart failure with preserved ejection fraction (HFpEF; LVEF >50%).As pharmacological treatment of heart failure…

    Source: Allen Press
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      Heart failure drug therapy: New treatments, new guidelines | #THIPubs @JRogersMD1 #THIFellowship | @Texas_Heart #THIJournal https://t.co/E7YRNcZ5Cj https://t.co/eXDjZOUA7k

  • Mashup Score: 0
    Using clinical decision support tools to increase defibrillator deactivations in dying patients - 2 year(s) ago

    Inadvertent automatic implantable cardioverter defibrillator (AICD) shocks at the end of life are distressing and should be avoided.1 2 Up to 65% of AICDs are active and up to 33% of patients with AICDs receive shocks within 24 hours of dying.3 Though guidelines encourage device discussions, one study demonstrated only 27% of clinicians brought up AICD deactivation.2 4 Since the Health…

    Source: BMJ Open Quality
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      Using clinical decision support tools to increase defibrillator deactivations in dying patients | #THIPubs @RamseyKalilMD #THIFellowship | @BMJOpenQuality https://t.co/VCK5UotgBA https://t.co/6S23Uljiv5

Load More